Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
出版年份 2022 全文链接
标题
Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
作者
关键词
-
出版物
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-01-30
DOI
10.1007/s00432-021-03885-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Achieving clinical success with BET inhibitors as anti-cancer agents
- (2021) Tatiana Shorstova et al. BRITISH JOURNAL OF CANCER
- Activating a collaborative innate-adaptive immune response to control metastasis
- (2021) Lijuan Sun et al. CANCER CELL
- Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes
- (2021) Laura Ardighieri et al. Frontiers in Immunology
- CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis
- (2020) Hui Yang et al. Molecular Cancer
- Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses
- (2020) Jesse M. Jaynes et al. Science Translational Medicine
- TIMER2.0 for analysis of tumor-infiltrating immune cells
- (2020) Taiwen Li et al. NUCLEIC ACIDS RESEARCH
- Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients
- (2020) Antonio Macciò et al. Scientific Reports
- Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology
- (2019) Gregor Sturm et al. BIOINFORMATICS
- Ovarian Cancer Immunotherapy: Turning up the Heat
- (2019) Eleonora Ghisoni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target
- (2019) Shaoping She et al. JOURNAL OF HEPATOLOGY
- Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.
- (2018) David Linehan et al. JOURNAL OF CLINICAL ONCOLOGY
- Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1- profile in a TLR4-dependent manner
- (2018) Carlos W Wanderley et al. CANCER RESEARCH
- Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression
- (2018) Benjamin J. Schmiedel et al. CELL
- Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4
- (2018) Alejandro Villar-Prados et al. MOLECULAR CANCER THERAPEUTICS
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor-associated macrophages: implications in cancer immunotherapy
- (2017) Amy J Petty et al. Immunotherapy
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)
- (2017) T Mitamura et al. ONCOGENE
- Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy
- (2017) B A Castro et al. ONCOGENE
- Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas
- (2017) D Yan et al. ONCOGENE
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy
- (2017) Yasmin A. Lyons et al. Oncotarget
- Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer
- (2016) Mingzhu Yin et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
- (2016) Timothy M Nywening et al. LANCET ONCOLOGY
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
- (2015) Xiaoguang Li et al. GUT
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- PC3-Secreted Microprotein Is a Novel Chemoattractant Protein and Functions as a High-Affinity Ligand for CC Chemokine Receptor 2
- (2014) X. Pei et al. JOURNAL OF IMMUNOLOGY
- CSF-1R inhibition alters macrophage polarization and blocks glioma progression
- (2013) Stephanie M Pyonteck et al. NATURE MEDICINE
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
- (2011) Bin-Zhi Qian et al. NATURE
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now